- The disease
- Mesothelin is a protein found at high levels on the surface of several hard-to-treat cancers, including malignant pleural mesothelioma (a cancer of the lung lining strongly linked to asbestos exposure), non-small cell lung cancer, ovarian cancer, and pancreatic cancer. These cancers are often diagnosed at an advanced stage and have limited treatment options. Mesothelioma in particular has very poor outcomes with standard chemotherapy and newer immunotherapy regimens. Mesothelin expression on tumour cells makes it a target for therapies designed to direct immune cells specifically to the cancer.
- What the asset is trying to do
- BZDS1901 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy, meaning immune cells are collected from the patient, genetically re-engineered in a laboratory, and then infused back. The CAR directs the engineered T-cells to recognise and attack mesothelin-expressing tumour cells. The therapy is described as 'armoured' because it also incorporates a nanobody — a small antibody fragment — that blocks the PD-1 immune checkpoint, a mechanism tumours use to suppress immune cell activity. BZDS1901 is licensed from SHcell, a Chinese cell therapy company, and is being developed in Australia through Adalta's AdCella subsidiary.
- What the trial is measuring, and why it matters
- The planned Australian Phase 1 trial is expected to enrol up to 18 patients and will primarily assess safety and tolerability of BZDS1901 in patients whose tumours express mesothelin (per Adalta announcements). Early-phase oncology trials of this type typically also collect data on how the drug behaves in the body (pharmacokinetics) and initial signals of anti-tumour activity, though the specific endpoints for this trial have not yet been publicly disclosed in detail. Regulatory advisors were appointed for BZDS1901 in May 2026 (per ASX announcement 2026-05-24), indicating the trial design and regulatory submission are in progress.
- Efficacy benchmarks in this setting
- In malignant pleural mesothelioma treated with first-line chemotherapy (pemetrexed plus platinum), objective response rates of approximately 41% and median overall survival of around 12 months have been reported in pivotal trials (Vogelzang et al, Journal of Clinical Oncology 2003). The addition of pembrolizumab (a PD-1 checkpoint inhibitor) to chemotherapy in first-line mesothelioma showed a median overall survival of 17.3 months versus 16.1 months for chemotherapy alone in the KEYNOTE-483 trial (Nowak et al, Annals of Oncology 2023). For mesothelin-targeted antibody-drug conjugates such as anetumab ravtansine, response rates in mesothelioma second-line settings have been modest in randomised trials (Kindler et al, Annals of Oncology 2017). The Chinese SHcell data cited for BZDS1901 (63.5% objective response rate and 73% 12-month overall survival in mesothelioma, per Adalta notes) were generated in a different patient population under different study conditions and are not statistically comparable to the figures above; no peer-reviewed publication or trial registry entry for those Chinese results has been identified in the information provided.